Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Donna S. Neuberg, D.Sc.

Co-Author

This page shows the publications co-authored by Donna Neuberg and Kimberly Stegmaier.
Connection Strength

0.276
  1. Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell. 2019 04 15; 35(4):664-676.e7.
    View in: PubMed
    Score: 0.053
  2. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 07; 65(7):e27062.
    View in: PubMed
    Score: 0.050
  3. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
    View in: PubMed
    Score: 0.044
  4. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
    View in: PubMed
    Score: 0.043
  5. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23.
    View in: PubMed
    Score: 0.038
  6. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res. 2014 Apr; 38(4):430-4.
    View in: PubMed
    Score: 0.037
  7. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996 Dec 01; 88(11):4252-8.
    View in: PubMed
    Score: 0.011
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.